Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Live Bifidobacterium Capsules as Adjuvant to Anti-TNF Therapy in Inflammatory Bowel Disease
ChiCTR2500108246Phase 4Recruiting
- Sponsor
- Renji Hospital
- Start
- Aug 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of live Bifidobacterium in autoimmune colitis, Crohn's disease and inflammatory bowel disease (IBD) (2 arms), sponsored by Renji Hospital. Primary endpoints: Simple Endoscopic Score for Crohn's Disease (SES-CD), Modified Mayo Score and 4 more. Started Aug 2025; status: recruiting.
02
Drugs
live Bifidobacterium
03
Conditions
autoimmune colitisCrohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on ChiCTR2500108246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108246.